The Primary Care Companion
PCC E-Lert/03.10.14
Figure 1. Change in Visual Analog Scale Score During the Study
Effects of Milnacipran on Neurocognition, Pain, and Fatigue in Fibromyalgia: A 13-Week, Randomized, Placebo-Controlled, Crossover Trial
Jeong Lan Kim, MD; Shilpa Rele, MHA; David M. Marks, MD; Prakash S. Masand, MD; Pallavi Yerramsetty; Robert A. Millet, MD; Richard S. Keefe, PhD; and Ashwin A. Patkar, MD
Is milnacipran a safe and effective treatment for improving cognitive function in fibromyalgia? To find out, the authors of this article conducted a 13-week trial. Patients were randomized to receive milnacipran or placebo for 6 weeks, followed by a 1-week washout and then cross over to the other arm for another 6 weeks. Assessments were performed at each visit.
[Abstract] [Full Text]
For more free peer-reviewed aricles, visit the Companion at PSYCHIATRIST.COM/PCC. If you are having trouble reading this E-Lert, see
To receive E-Lerts from both The Journal of Clinical Psychiatry and The Primary Care Companion, update your profile.
Like us on Facebook Follow us in Twitter
You are receiving this update as a benefit of your membership.
To ensure delivery of these messages add to your address book. If you would not like to receive further E-Lerts, go to and click the "Unsubscribe from E-Lerts" link. If you are having trouble unsubscribing, contact the web administrator for assistance.
If you are having trouble with your membership, contact our circulation department. Direct any other questions or comments to the web administrator.
Please do not reply directly to this e-mail. Neither nor any of its family of websites will ask you to send us profile information via e-mail.
If you cannot read this go to
Physicians Postgraduate Press, Inc. | 850 Ridge Lake Boulevard, Suite 300 | Memphis, TN 38120
© Copyright 2014, Physicians Postgraduate Press, Inc. All rights reserved.